- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| 13.11. | Lyell Immunopharma reports Q3 results | 3 | Seeking Alpha | ||
| 12.11. | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | Lyell Immunopharma buys exclusive global rights to colorectal cancer drug | 1 | Seeking Alpha | ||
| 10.11. | Lyell Immunopharma, Inc: Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer | 60 | GlobeNewswire (Europe) | LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal... ► Artikel lesen | |
| 10.11. | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11. | Lyell Immunopharma: Vielversprechende Daten zu dualer CAR-T-Zelltherapie bei Lymphomen | 1 | Investing.com Deutsch | ||
| 03.11. | Lyell Immunopharma, Inc: Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| 03.11. | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.09. | Lucid Capital Markets initiates Lyell Immunopharma stock with Buy rating | 2 | Investing.com | ||
| 16.09. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.08. | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 | 329 | GlobeNewswire (Europe) | Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE... ► Artikel lesen | |
| 12.08. | Lyell Immunopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.07. | Lyell Immunopharma announces up to $100 million equity private placement | 1 | Seeking Alpha | ||
| 25.07. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.07. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces up to $100 Million Equity Private Placement | 3 | GlobeNewswire (USA) | ||
| 18.07. | Lyell Immunopharma registers 625,000 shares for resale | 1 | Seeking Alpha | ||
| 26.06. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Lyell Immunopharma price target raised to $10 from $1 at H.C. Wainwright | 1 | Investing.com | ||
| 23.06. | Lyell Immunopharma, Inc: Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series | 3 | GlobeNewswire (USA) |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,026 | -12,67 % | MEDIGENE AG stürzt ab - ich traue meinen Augen kaum! | ||
| AMGEN | 290,05 | -1,02 % | Dividendenbekanntmachungen (21.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,065 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,27 USD 0,2341 EUR ALPHAMIN... ► Artikel lesen | |
| BIOGEN | 151,10 | -0,76 % | Biogen Inc.: Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments | - Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative... ► Artikel lesen | |
| EDITAS MEDICINE | 2,077 | -0,95 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GALAPAGOS NV | 26,600 | 0,00 % | Gilead wants us to 'rebuild': Why Galapagos isn't allowed to go extinct after turbulent year | ||
| IMMATICS | 8,885 | +0,34 % | Immatics Announces Third Quarter 2025 Financial Results and Business Update | Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,090 | +2,83 % | Autolus Therapeutics plc - S-8, Securities to be offered to employees in employee benefit plans | ||
| IGM BIOSCIENCES | 1,080 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.08.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 14.08.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.08.2025.ISIN NameCA87168M1068 SYNEX... ► Artikel lesen | |
| TANGO THERAPEUTICS | 10,030 | +12,70 % | Tango Therapeutics launches $100M at-the-market stock offering | ||
| TSCAN THERAPEUTICS | 0,960 | -1,79 % | TScan Therapeutics, Inc.: TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 | Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,56 | -0,13 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| NUVALENT | 105,88 | -1,97 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,170 | +8,45 % | Recursion (RXRX) Jumps 8% on Bargain-Hunting | ||
| COGENT BIOSCIENCES | 36,770 | +5,97 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| JANUX THERAPEUTICS | 28,800 | +0,73 % | Wolfe Research initiates Janux Therapeutics stock with Peerperform rating |
Das Unternehmen LYELL IMMUNOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 18,360 Euro und damit +4,41 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYELL IMMUNOPHARMA INC finden Sie auf Wallstreet Online.